Journal Mobile Options
Table of Contents
Vol. 51, No. 4, 2005
Issue release date: July 2005
Chemotherapy 2005;51:177–181
(DOI:10.1159/000086919)

European Status of Resistance in Nosocomial Infections

Goossens H.
University Hospital Antwerp, Antwerp, Belgium, and Leiden University Medical Center, Leiden, Netherlands

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Surveillance studies are mandatory to carefully monitor changing trends in Europe. Methods: Surveys on antibiotic resistance conducted in European hospitals were reviewed. Data were obtained from own studies, through searches of Medlines, Pubmed, abstracts and posters presented at meetings, from the World Wide Web and from surveillance studies conducted by the pharmaceutical industry. Results: A high prevalence of MRSA was found in most European hospitals, except in northern Europe, and an increasing trend in non-intensive care unit patients was observed. In most European hospitals, the prevalence of infections caused by vancomycin-resistant enterococci remains very low and most outbreaks have occurred in at-risk wards. No major changes of resistance among Enterobacteriaceae were observed. Very few of the major antibiotics are now reliably effective for the treatment of severe nosocomial carbapenem-resistant Acinetobacter infections. Conclusions: Although antimicrobial resistance appears to be increasing all over Europe, it is difficult to accurately estimate the extent of this emerging problem. One of the main reasons for this can be attributed to the fact that the published susceptibility data are difficult to compare due to the different methods used, population bias, and clonal variation. Increasing antimicrobial resistance necessitates a critical appraisal of the remaining antibiotic treatment options.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. National Nosocomial Infections Surveillance (NNIS): National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990–May 1999, issued June 1999. Am J Infect Control 199;27:520–532.
  2. Goossens H: The epidemiology of vancomycin-resistant enterococci. Curr Opin Infect Dis 1999;12:537–541.

    External Resources

  3. Bradford PA: Extended-spectrum beta-lactamases in the 21st century: Characterisation, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933–951.
  4. Neuwirth C, Siebor E, Lopez J, Pechinot A, Kazmierczak A: Outbreak of TEM-24-producing Enterobacter aerogenes in an intensive care unit and dissemination of the extended-spectrum β-lactamase to other members of the family Enterobacteriaceae. J ClinMicrobiol 1996;34:76–79.
  5. Pitout JDD, Thomson KS, Hanson ND, Ehrardt AF, Coudron P, Sanders CC: Plasmid-mediated resistance to expanded-spectrum cephalosporins among Enterobacter aerogenes strains. Antimicrob Agents Chemother 1998;42:596–600.
  6. Van Looveren M, Goossens H, ARPAC Steering Group: Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004;10:684–704.
  7. Bernards AT, de Beaufort AJ, Dijkshoorn L, van Boven CP: Outbreak of septicaemia in neonates caused by Acinetobacter junii investigated by amplified ribosomal DNA restriction analysis (ARDRA) and four typing methods. J Hosp Infect 1997;35:129–140.
  8. Dijkshoorn L, Aucken H, Gerner-Smidt P, Janssen P, Kaufmann ME, Garaizar J, et al: Comparison of outbreak and nonoutbreak Acinetobacter baumannii strains by genotypic and phenotypic methods. J Clin Microbiol 1996;34:1519–1525.
  9. Afzal-Shah M, Livermore DM: Worldwide emergence of carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 1998;41:576–577.
  10. Bou G, Cervero G, Dominguez MA, Quereda C, Martinez-Beltran J: Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: High-level carbapenem resistance in A. baumannii is not due solely to the presence of β-lactamases. J Clin Microbiol 2000;38:3299–3305.
  11. Goossens H, Jabes D, Rossi R, Lammens C, Privitera G, Courvalin P: European survey of vancomycin-resistant enterococci in at-risk hospital wards and in vitro susceptibility testing of ramoplanin against these isolates. J Antimicrob Chemother 2003;51(suppl 3):iii, 5–12.
  12. Pfaller MA, Jones RN, Doern GV, Kugler K, the SENTRY Participants Group: Bacterial pathogens isolated from patients with bloodstream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998;42:1762–1770.
  13. Rodriguez-Villalobos H, Jones RN, Struelens MJ, the European SENTRY Participants: Epidemiology of antibiotic resistance of bacterial pathogens in intensive care units from the SENTRY surveillance program in Europe 2000. 12th Eur Congr Clin Microbiol Infect Dis, Milan, 2002.
  14. Rodriguez-Villalobos H, Struelens MJ, Jones RN, the European SENTRY Participants: Frequency and resistance rates of Pseudomonas aeruginosa in Europe: Update from SENTRY surveillance program 2000. 12th Eur Congr Clin Microbiol Infect Dis, Milan, 2002.
  15. Rodriguez-Villalobos H, Struelens MJ, Jones RN, the European SENTRY Participants: Prevalence and resistance rates of Enterobacter spp in nosocomial infections, Euro-SENTRY antimicrobial surveillance program, 1997–2001. 12th Eur Congr Clin Microbiol Infect Dis, Milan, 2002.
  16. Rodriguez-Villalobos H, Struelens MJ, Jones R, European SENTRY Participants: Resistance in pathogens from patients admitted to intensive care units (ICU). A report from the SENTRY surveillance program Europe 2002–2002. 43rd Intersci Conf Antimicrob Agents Chemother, Chicago, 2003.
  17. Rodriguez-Villalobos H, Struelens MJ, Jones R, European SENTRY Participants: Trends in antimicrobial resistance rates of Staphylococcus aureus causing bloodstream infection and nosocomial pneumonia. A report from the EURO-SENTRY surveillance program 2000–2002. 43rd Intersci Conf Antimicrob Agents Chemother, Chicago, 2003.
  18. Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J: Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis 2000;30:454–460.
  19. Jones ME, Schmitz FJ, Fluit AC, Acar J, Gupta R, Verhoef J: Frequency of occurrence and antimicrobial susceptibility of bacterial pathogens associated with skin and soft tissue infections during 1997 from an International Surveillance Programme. SENTRY Participants Group. Eur J Clin Microbiol Infect Dis 1999;18:403–408.
  20. Schmitz FJ, Verhoef J, Fluit AC: Prevalence of aminoglycoside resistance in 20 European university hospitals participating in the European SENTRY Antimicrobial Surveillance Programme. Eur J Clin Microbiol Infect Dis 1999;18:414–421.
  21. Schmitz FJ, Verhoef J, Fluit AC: Comparative activities of six different fluoroquinolones against 9,682 clinical bacterial isolates from 20 European university hospitals participating in the European SENTRY surveillance programme. The SENTRY participants group. Int J Antimicrob Agents 1999;12 311–317.
  22. Decousser, JW, Pina P, Picot F, Delalande C, Pangon B, Corvalin P, Allouch P, ColBVH Study Group: Frequency of isolation and antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections: A French prospective national survey. J Antimicrob Chemother 20003;51:1213–1222.
  23. European Antimicrobial Resistance Surveillance System (EARSS): www.earss.rivm.nl.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50